Ignite Creation Date:
2024-07-17 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06465186
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-06-13
Brief Title:
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis MK-6024-017
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Phase 2a Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide MK-6024 in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat called metabolic dysfunction-associated steatohepatitis MASH MASH was formerly called non-alcoholic steatohepatitis NASH Researchers want to learn if a study medicine called efinopegdutide can treat MASHThe goals of this study are to learn
If efinopegdutide can lower the amount of fat inflammation and scarring fibrosis in the liver
About the safety of efinopegdutide and how well people tolerate it
If efinopegdutide can lower the amount of fat inflammation and scarring fibrosis in the liver
About the safety of efinopegdutide and how well people tolerate it
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2024-510923-20 | OTHER | None | None |
| MK-6024-017 | OTHER | None | None |